Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Frontage Labs Expands Early Phase Clinical Capabilities | Contract Pharma

What are you searching for?

Sign in
Breaking News

Frontage Labs Expands Early Phase Clinical Capabilities

Phase I clinical unit in Secaucus to conduct large scale Phase I and Bioequivalence studies and radiolabeled human AME research.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Frontage Labs

Frontage Clinical Services at 200 Meadowlands Parkway, Secaucus, NJ

Frontage Laboratories, Inc., a global Contract Research, Development and Manufacturing Organization (CRDMO), expanded its early phase clinical research capabilities across the U.S. and China. This expansion aims to enhance the company’s ability to support pharmaceutical and biotech partners with accelerated, high‑quality clinical development services.

The company’s U.S. operations now include a 160‑bed, 36,000‑sq.‑ft. Phase I clinical unit in Secaucus, NJ, designed to conduct large‑scale Phase I and Bioequivalence (BE) studies as well as radiolabeled human AME research. The company strengthened its C14‑hAME capabilities through a dedicated unit staffed by licensed radiation experts and supported by an onsite nuclear pharmacy for sterile and non‑sterile radiolabeled compounding. Frontage has successfully executed combined hAME and Absolute Bioavailability studies aligned with the FDA’s 2024 guidance.

Frontage is also expanding into Oncology Phase I trials through partnerships with regional hospitals and clinical networks, enabling patient‑based research across key cancer indications.

Frontage’s U.S. clinical units are positioned to manage complex, high‑volume BE programs. Collaboration with Frontage China enables flexible Multi‑Regional Clinical Trial (MRCT) execution to support global program timelines.

These capabilities are integrated through Frontage’s combined Bioanalytical & Central Lab services, DMPK, and CMC—including drug product manufacturing in Pennsylvania—to reduce handoffs, accelerate timelines, and lower overall study costs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics